JP2018509907A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509907A5 JP2018509907A5 JP2017548919A JP2017548919A JP2018509907A5 JP 2018509907 A5 JP2018509907 A5 JP 2018509907A5 JP 2017548919 A JP2017548919 A JP 2017548919A JP 2017548919 A JP2017548919 A JP 2017548919A JP 2018509907 A5 JP2018509907 A5 JP 2018509907A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 982
- 230000027455 binding Effects 0.000 claims description 377
- 239000000427 antigen Substances 0.000 claims description 321
- 102000036639 antigens Human genes 0.000 claims description 321
- 108091007433 antigens Proteins 0.000 claims description 321
- 239000012634 fragment Substances 0.000 claims description 246
- 210000004027 cell Anatomy 0.000 claims description 197
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 83
- 102100023123 Mucin-16 Human genes 0.000 claims description 83
- 238000000338 in vitro Methods 0.000 claims description 52
- 108010082117 matrigel Proteins 0.000 claims description 52
- 230000009545 invasion Effects 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 49
- 229910052757 nitrogen Inorganic materials 0.000 claims description 32
- 230000013595 glycosylation Effects 0.000 claims description 31
- 238000006206 glycosylation reaction Methods 0.000 claims description 31
- 108091033319 polynucleotide Proteins 0.000 claims description 24
- 102000040430 polynucleotide Human genes 0.000 claims description 24
- 239000002157 polynucleotide Substances 0.000 claims description 24
- 125000000539 amino acid group Chemical group 0.000 claims description 22
- QLTSDROPCWIKKY-PMCTYKHCSA-N beta-D-glucosaminyl-(1->4)-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1 QLTSDROPCWIKKY-PMCTYKHCSA-N 0.000 claims description 19
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 14
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229910052698 phosphorus Inorganic materials 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- 239000002254 cytotoxic agent Substances 0.000 claims description 7
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000012216 imaging agent Substances 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000003101 oviduct Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000004303 peritoneum Anatomy 0.000 claims 1
- 230000002163 immunogen Effects 0.000 description 54
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 53
- 108010015899 Glycopeptides Proteins 0.000 description 53
- 102000002068 Glycopeptides Human genes 0.000 description 53
- 150000001720 carbohydrates Chemical class 0.000 description 14
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 150000002016 disaccharides Chemical class 0.000 description 6
- 229940127121 immunoconjugate Drugs 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical class CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 150000004044 tetrasaccharides Chemical class 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134402P | 2015-03-17 | 2015-03-17 | |
| US62/134,402 | 2015-03-17 | ||
| PCT/US2016/022643 WO2016149368A1 (en) | 2015-03-17 | 2016-03-16 | Anti-muc16 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020162274A Division JP2021000132A (ja) | 2015-03-17 | 2020-09-28 | 抗ｍｕｃ１６抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509907A JP2018509907A (ja) | 2018-04-12 |
| JP2018509907A5 true JP2018509907A5 (enExample) | 2019-04-25 |
| JP6968698B2 JP6968698B2 (ja) | 2021-11-24 |
Family
ID=55755670
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548919A Active JP6968698B2 (ja) | 2015-03-17 | 2016-03-16 | 抗ｍｕｃ１６抗体及びその使用 |
| JP2020162274A Withdrawn JP2021000132A (ja) | 2015-03-17 | 2020-09-28 | 抗ｍｕｃ１６抗体及びその使用 |
| JP2022091593A Withdrawn JP2022116314A (ja) | 2015-03-17 | 2022-06-06 | 抗ｍｕｃ１６抗体及びその使用 |
| JP2024232825A Pending JP2025061682A (ja) | 2015-03-17 | 2024-12-27 | 抗ｍｕｃ１６抗体及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020162274A Withdrawn JP2021000132A (ja) | 2015-03-17 | 2020-09-28 | 抗ｍｕｃ１６抗体及びその使用 |
| JP2022091593A Withdrawn JP2022116314A (ja) | 2015-03-17 | 2022-06-06 | 抗ｍｕｃ１６抗体及びその使用 |
| JP2024232825A Pending JP2025061682A (ja) | 2015-03-17 | 2024-12-27 | 抗ｍｕｃ１６抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11066480B2 (enExample) |
| EP (2) | EP4190817A1 (enExample) |
| JP (4) | JP6968698B2 (enExample) |
| KR (1) | KR102618312B1 (enExample) |
| CN (2) | CN107667120B (enExample) |
| AU (3) | AU2016233309B2 (enExample) |
| CA (1) | CA2979976A1 (enExample) |
| ES (1) | ES2929614T3 (enExample) |
| IL (3) | IL296062A (enExample) |
| MX (2) | MX391249B (enExample) |
| RU (1) | RU2758113C2 (enExample) |
| SG (1) | SG11201707538XA (enExample) |
| WO (1) | WO2016149368A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2621874T3 (es) | 2010-03-26 | 2017-07-05 | Memorial Sloan-Kettering Cancer Center | Anticuerpos para MUC16 y métodos de uso de los mismos |
| IL278574B2 (en) | 2014-11-12 | 2024-11-01 | Seagen Inc | Glycan-interacting compounds and methods of use |
| MX391249B (es) | 2015-03-17 | 2025-03-21 | Memorial Sloan Kettering Cancer Center | Anticuerpos anti-muc16 y sus usos. |
| AU2016342041B2 (en) | 2015-10-23 | 2021-12-02 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
| WO2017083582A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| RS64691B1 (sr) * | 2016-09-23 | 2023-11-30 | Regeneron Pharma | Bispecifična anti-muc16-cd3 antitela i konjugati anti-muc16 sa lekom |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| WO2018098348A1 (en) | 2016-11-23 | 2018-05-31 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a cd38 inhibitor and methods of use thereof |
| KR20240044544A (ko) | 2017-03-03 | 2024-04-04 | 씨젠 인크. | 글리칸-상호작용 화합물 및 사용 방법 |
| WO2018200585A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and secondary effectors and uses thereof |
| EA039842B1 (ru) * | 2017-09-14 | 2022-03-18 | Ридженерон Фармасьютикалз, Инк. | Биспецифичные анти-muc16-cd3 антитела и конъюгаты анти-muc16-лекарственное средство |
| US12180285B2 (en) | 2018-02-01 | 2024-12-31 | Memorial Sloan Kettering Cancer Center | Antibodies to galectin-3 and methods of use thereof |
| WO2019213747A1 (en) * | 2018-05-09 | 2019-11-14 | Quest Pharmatech Inc. | Muc16 monoclonal antibody and uses thereof |
| CN110527667A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 一种靶向muc16的嵌合抗原受体和嵌合抗原受体t细胞及其制备方法和应用 |
| CN110526977A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 一种靶向muc1的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN110526974A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 一种靶向muc16的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN110526988A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 一种靶向muc1的嵌合抗原受体和嵌合抗原受体t细胞及其制备方法和应用 |
| EA202191058A1 (ru) * | 2018-11-16 | 2021-10-07 | Мемориал Слоун Кеттеринг Кэнсер Сентр | Антитела против муцина-16 и способы их применения |
| JP7675016B2 (ja) * | 2019-05-08 | 2025-05-12 | メモリアル スローン ケタリング キャンサー センター | ムチン－１６に対するヒト化抗体およびそれを使用する方法 |
| KR20220024035A (ko) | 2019-06-21 | 2022-03-03 | 리제너론 파마슈티칼스 인코포레이티드 | Muc16 및 cd3에 결합하는 이중 특이적 항원 결합 분자와 4-1bb 공동 자극의 병용 |
| US20210040174A1 (en) * | 2019-08-08 | 2021-02-11 | Navrogen, Inc. | Composition and Use of Humoral Immune Suppressor Antagonists for the Treatment of Humoral Immune Suppressed Diseases |
| US20230340623A1 (en) * | 2020-06-30 | 2023-10-26 | Universiteit Antwerpen | Mucins and isoforms thereof in diseases characterized by barrier dysfunction |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| JP2024500189A (ja) | 2020-12-21 | 2024-01-04 | アロジーン セラピューティクス，インコーポレイテッド | プロテアーゼ活性化ｃｄ４５ゲートｃａｒ |
| KR20230142470A (ko) | 2021-01-29 | 2023-10-11 | 알로젠 테라퓨틱스 인코포레이티드 | 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃 |
| WO2022204249A1 (en) * | 2021-03-24 | 2022-09-29 | Memorial Sloan-Kettering Cancer Center | Variants of humanized anti-muc16 ectodomain antibodies for treatment of muc16 overexpressing tumors |
| CN113061186B (zh) * | 2021-04-09 | 2022-05-13 | 福州迈新生物技术开发有限公司 | 抗ca125蛋白的单克隆抗体及其细胞株、制备方法和应用 |
| CN115260305B (zh) * | 2021-04-29 | 2025-02-28 | 郑州大学 | 抗SARS-CoV-2 RBD单克隆抗体和应用 |
| CN114835805B (zh) * | 2022-06-10 | 2023-06-06 | 郑州大学 | 抗SARS-CoV-2 spike蛋白的单克隆抗体及应用 |
| US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
| US20240262929A1 (en) * | 2023-02-06 | 2024-08-08 | Ibio, Inc. | Anti-muc16 antibodies |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| CN118684782A (zh) * | 2024-07-17 | 2024-09-24 | 武汉科技大学 | 一种muc16和folr1双靶点嵌合抗原受体dcar-16-r1及应用 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| US4824659A (en) | 1985-06-07 | 1989-04-25 | Immunomedics, Inc. | Antibody conjugates |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US4978745A (en) | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990013678A1 (en) | 1989-05-08 | 1990-11-15 | Farber Mark I | Process and apparatus for the recovery of precious metals from slag, tailings and other materials |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
| ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5976818A (en) | 1991-12-16 | 1999-11-02 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibodies which identify the glycoprotein carrying the CA 125 epitope |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
| PL172758B1 (pl) | 1992-10-19 | 1997-11-28 | Dura Pharma Inc | Inhalator do proszków suchych PL PL PL PL PL PL PL |
| US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
| AU5883694A (en) | 1993-01-19 | 1994-08-15 | Glaxo Group Limited | Device |
| PL310327A1 (en) | 1993-02-12 | 1995-12-11 | Univ Leland Stanford Junior | Adjustable transcription of target genes and other biological processes |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| BR9606706A (pt) | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
| US6065472A (en) | 1996-01-03 | 2000-05-23 | Glaxo Wellcome Inc. | Multidose powder inhalation device |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US6027947A (en) | 1996-08-20 | 2000-02-22 | Ramtron International Corporation | Partially or completely encapsulated top electrode of a ferroelectric capacitor |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
| US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
| US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CU22731A1 (es) | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
| WO1999055369A1 (en) | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| CA2388063C (en) | 1999-11-24 | 2010-06-08 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| ATE440111T1 (de) | 1999-11-29 | 2009-09-15 | Bac Ip B V | Immobilisierte antigenbindende moleküle aus einer domäne |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| AU2002254615A1 (en) * | 2001-04-17 | 2002-10-28 | The Board Of Trustees Of The University Of Arkansas | Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |
| ITRM20010408A1 (it) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| EP1536814A4 (en) | 2002-07-03 | 2006-02-15 | Immunogen Inc | ANTIBODIES AGAINST MUC1 AND MUC16 NOT RELEASED AND USES THEREOF |
| WO2004020454A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
| GB2424070B (en) | 2002-11-14 | 2007-06-27 | Univ Nottingham | Methods for preparing tumour marker proteins |
| WO2004073656A2 (en) | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| AU2004280333A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Llc | Humanization of antibodies |
| JP2008507255A (ja) | 2004-03-12 | 2008-03-13 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０ |
| EP1753880A4 (en) * | 2004-05-14 | 2010-07-14 | Univ California | METHOD FOR THE TREATMENT OF CANCER USING MONOCLONAL ANTI-WNT2 ANTIBODIES AND siRNA |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| ES2621874T3 (es) | 2010-03-26 | 2017-07-05 | Memorial Sloan-Kettering Cancer Center | Anticuerpos para MUC16 y métodos de uso de los mismos |
| AU2011268110B2 (en) | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
| WO2015006043A1 (en) * | 2013-07-09 | 2015-01-15 | Board Of Regents Of The University Of Nebraska | Novel method of targeting glycoproteins to treat cancer |
| MX391249B (es) | 2015-03-17 | 2025-03-21 | Memorial Sloan Kettering Cancer Center | Anticuerpos anti-muc16 y sus usos. |
-
2016
- 2016-03-16 MX MX2017011822A patent/MX391249B/es unknown
- 2016-03-16 IL IL296062A patent/IL296062A/en unknown
- 2016-03-16 SG SG11201707538XA patent/SG11201707538XA/en unknown
- 2016-03-16 KR KR1020177029700A patent/KR102618312B1/ko active Active
- 2016-03-16 JP JP2017548919A patent/JP6968698B2/ja active Active
- 2016-03-16 RU RU2017134592A patent/RU2758113C2/ru active
- 2016-03-16 AU AU2016233309A patent/AU2016233309B2/en active Active
- 2016-03-16 CN CN201680028517.9A patent/CN107667120B/zh active Active
- 2016-03-16 EP EP22192814.6A patent/EP4190817A1/en active Pending
- 2016-03-16 CN CN202210174122.7A patent/CN115368460A/zh active Pending
- 2016-03-16 EP EP16716959.8A patent/EP3271398B1/en active Active
- 2016-03-16 US US15/558,694 patent/US11066480B2/en active Active
- 2016-03-16 CA CA2979976A patent/CA2979976A1/en active Pending
- 2016-03-16 WO PCT/US2016/022643 patent/WO2016149368A1/en not_active Ceased
- 2016-03-16 ES ES16716959T patent/ES2929614T3/es active Active
-
2017
- 2017-09-14 IL IL254517A patent/IL254517B/en active IP Right Grant
- 2017-09-14 MX MX2022003891A patent/MX2022003891A/es unknown
-
2020
- 2020-09-28 JP JP2020162274A patent/JP2021000132A/ja not_active Withdrawn
-
2021
- 2021-05-20 IL IL283321A patent/IL283321A/en unknown
- 2021-07-14 US US17/375,048 patent/US12466894B2/en active Active
-
2022
- 2022-02-11 AU AU2022200931A patent/AU2022200931A1/en not_active Abandoned
- 2022-06-06 JP JP2022091593A patent/JP2022116314A/ja not_active Withdrawn
-
2024
- 2024-12-27 JP JP2024232825A patent/JP2025061682A/ja active Pending
-
2025
- 2025-04-17 AU AU2025202713A patent/AU2025202713A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509907A5 (enExample) | ||
| RU2017134592A (ru) | Антитела к muc16 и их применение | |
| CN107531786B (zh) | 抗axl拮抗抗体 | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| US20210024635A1 (en) | Anti-wt1/hla-specific antibodies | |
| JP2024053016A (ja) | Ｇタンパク質共役受容体を標的化する抗体および使用の方法 | |
| JP2005507635A5 (enExample) | ||
| JP6077745B2 (ja) | 抗ポドプラニン抗体、及び抗ポドプラニン抗体を含む医薬組成物 | |
| JP7257971B2 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| TWI821699B (zh) | 抗b7h4抗體及其雙抗和應用 | |
| CA2866612A1 (en) | Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof | |
| BR112021003018A2 (pt) | anticorpos monoclonais contra tim-3 humana | |
| US11655297B2 (en) | ILDR2 antagonists and combinations thereof | |
| TW202146455A (zh) | 抗axl抗體及組合物 | |
| CN119409832B (zh) | 靶向PD-L1和TGF-β的双功能分子 | |
| WO2019136516A1 (en) | Methods of treating myocarditis and/or cardiomyopathy and reagents therefor | |
| KR20250094708A (ko) | 자가항체-유발성 질환의 치료에서 면역글로불린의 제거를 위한 다중특이적 분자 | |
| US10584175B2 (en) | FN14-binding proteins and uses thereof | |
| WO2021000004A1 (en) | Methods of treating myocarditis and/or cardiomyopathy and reagents therefor | |
| US20240262929A1 (en) | Anti-muc16 antibodies | |
| KR20250110219A (ko) | 표피 성장 인자 수용체 변이체 iii 항체 | |
| EP2319871A1 (en) | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same | |
| EP2308896A1 (en) | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |